Stock A032300 KOREA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials KOREA PHARMA Co., Ltd.

Equities

A032300

KR7032300006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
18,000 KRW -0.17% Intraday chart for KOREA PHARMA Co., Ltd. -2.07% -23.89%
28/05 NetScientific backs Wanda; Inspirit Energy wins deal AN
28/05 Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in Korea CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 2,42,129 5,29,520 2,33,403 2,57,943
Enterprise Value (EV) 1 2,37,216 5,20,707 2,24,952 2,44,495
P/E ratio 68.4 x 83.9 x -209 x 3,079 x
Yield - - - -
Capitalization / Revenue 3.39 x 6.65 x 2.88 x 3.1 x
EV / Revenue 3.32 x 6.54 x 2.78 x 2.94 x
EV / EBITDA 34.8 x 70.4 x 26.3 x 28.3 x
EV / FCF -50.8 x 519 x 161 x -144 x
FCF Yield -1.97% 0.19% 0.62% -0.69%
Price to Book 5.21 x 9.21 x 3.9 x 3.76 x
Nbr of stocks (in thousands) 10,907 10,907 10,907 10,907
Reference price 2 22,200 48,550 21,400 23,650
Announcement Date 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 60,484 66,136 71,510 79,577 81,029 83,240
EBITDA 1 6,536 8,860 6,824 7,391 8,567 8,653
EBIT 1 5,684 7,215 4,604 5,014 6,187 5,840
Operating Margin 9.4% 10.91% 6.44% 6.3% 7.64% 7.02%
Earnings before Tax (EBT) 1 4,781 6,958 3,768 5,208 -1,780 2,014
Net income 1 3,828 5,528 3,159 6,368 -1,119 83.76
Net margin 6.33% 8.36% 4.42% 8% -1.38% 0.1%
EPS 2 444.0 629.0 324.3 579.0 -102.6 7.680
Free Cash Flow 1 3,516 7,221 -4,674 1,004 1,395 -1,693
FCF margin 5.81% 10.92% -6.54% 1.26% 1.72% -2.03%
FCF Conversion (EBITDA) 53.8% 81.5% - 13.58% 16.29% -
FCF Conversion (Net income) 91.85% 130.63% - 15.76% - -
Dividend per Share - - - - - -
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 11,263 6,616 - - - -
Net Cash position 1 - - 4,913 8,813 8,451 13,449
Leverage (Debt/EBITDA) 1.723 x 0.7467 x - - - -
Free Cash Flow 1 3,516 7,221 -4,674 1,004 1,395 -1,693
ROE (net income / shareholders' equity) 19.1% 22.6% 8.64% 12.3% -1.91% 0.13%
ROA (Net income/ Total Assets) 6.15% 6.99% 3.89% 2.97% 2.97% 2.89%
Assets 1 62,216 79,048 81,288 2,14,112 -37,672 2,894
Book Value Per Share 2 2,580 3,027 4,264 5,269 5,484 6,288
Cash Flow per Share 2 835.0 1,188 1,546 5,184 769.0 3,798
Capex 1 1,734 1,348 1,974 2,552 2,465 1,531
Capex / Sales 2.87% 2.04% 2.76% 3.21% 3.04% 1.84%
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KOREA PHARMA CO., LTD. Stock KOREA PHARMA Co., Ltd.
-23.89% 141M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.93% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.85% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.62% 225B
NOVARTIS AG Stock Novartis AG
+12.63% 218B
AMGEN INC. Stock Amgen Inc.
+8.61% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A032300 Stock
  4. Financials KOREA PHARMA Co., Ltd.